Cleveland Diagnostics: Improving The PSA Test
A new prostate cancer assay that uniquely defines blood-based biomarkers could restore confidence in the controversial PSA (prostate specific antigen) screening test. Cleveland Diagnostics Inc.’s PSA/SIA test detects cancer-specific changes to the three-dimensional structure of a PSA protein molecule, as opposed to merely measuring the amount of PSA in the blood via a standard PSA test.
You may also be interested in...
While the PSA test is still widely recognized as a valuable prostate cancer screening tool, its dismal accuracy record has created an acute need for more effective and informative alternatives, and the field of molecular diagnostics, based on gene-based biomarkers, is leading the charge.
Marks appeared to use the variable EUA bar to justify what many viewed as early mistakes by FDA during COVID-19, and to emphasize the importance of physician awareness of the strength of evidence used to authorize a drug.
Patent office could request information from FDA that is material to patentability, speakers at USPTO-FDA ‘listening session’ advise the agencies. Information exchange raises questions about trade secret protection and burdens on agencies.